|
|
| Product Name: | HIV-2 GP36 | | Synonyms: | Anti-HIV2 gp36 antibody;HIV-2;HIV-2 GP36;Recombinant HIV-2 gp36 | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | HIV protein | | Mol File: | Mol File | ![HIV-2 GP36 Structure]() |
| | HIV-2 GP36 Chemical Properties |
| | HIV-2 GP36 Usage And Synthesis |
| Description | HIV-2 gp36 is full length chemically synthesized polypeptide sequence of HIV-2 envelope immunodominant regions. | | Source | Synthetic | | Applications | HIV-2 gp36 antigen is suitable for ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems. | | Specificity | Immunoreactive with all sera of HIV-2 infected individuals. | | Background | HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2.
HIV-2 is less infectious in the early stages of the virus than with HIV-1.
The infectiousness of HIV-2 increases as the virus progresses.
Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion.
HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition. |
| | HIV-2 GP36 Preparation Products And Raw materials |
|